Cantor Fitzgerald Initiates Coverage On Eupraxia Pharmaceuticals with Overweight Rating, Announces Price Target of $11

Benzinga · 07/24 11:08
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Overweight rating and announces Price Target of $11.